Allogeneic Cell Therapies – An Emerging Modality in Therapeutics

Cell therapy refers to the introduction of active, healthy cells into a patient’s body in order to replace the damaged or previously compromised tissues. The cells used in the cell therapy can be from the patient’s own body (autologous) or from a donor (allogeneic). In allogeneic cell therapies, the cells are engineered (to elicit a desired therapeutic response) and amplified in-vitro. The modified cells can be preserved in a cell bank or administered to the patients. According to the Alliance for Regenerative Medicine, the number of clinical trials being conducted for allogeneic cell-based cancer therapies increased by 30% over the past five years.

Allogeneic Cell Therapies Sources

Allogeneic cell therapy can be derived from different sources, such as adipose tissue, bone marrow, peripheral blood, placenta, stem cells and umbilical cord.

Types of Allogeneic Cell Therapies

The allogeneic cell therapies can be categorized into the following types:

Allogeneic Cell Therapy categories

Advantages of Allogeneic Cell Therapies

Allogeneic cell therapies offer various advantages over other types of cell therapies, making them a promising approach for the treatment of various diseases, including autoimmune diseases, cancer, genetic disorders, and infectious diseases.

Leading companies operating in this reports are Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellenkos, Cell2Cure, Celularity, Cellular Biomedicine Group, CHABiotech, CRISPR Therapeutics, Fate Therapeutics

Advantages of Allogeneic Cell Therapies

Recent Developments in Allogeneic Cell Therapy Domain

  • In December 2022, the European Commission approved the first allogeneic, T-cell immunotherapy, Ebvallo (developed by Atara Biotherapeutics) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
  • In December 2022, the US FDA granted Fast Track Designation to CB-010 (developed by Caribou Biosciences) for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
  • In September 2022, the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130 (developed by CRISPR Therapeutics) for the treatment of cutaneous T-Cell lymphomas.
  • In July 2022, the US FDA granted Fast Track Designation and Rare Pediatric Disease Designation (RPDD) to WU-CART-007 (developed by Wugen) for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia / lymphoblastic lymphoma.
  • In April 2022, the US FDA granted orphan drug designation to ALLO-605 (developed by Allogene Therapeutic) for the treatment of advanced multiple myeloma.

Future Perspectives

Allogeneic cell therapy are off-the-shelf therapies that allow a single source of cells to treat multiple individuals and have endured as an effective treatment option for malignant as well as non-malignant disorders. These therapies are presently being investigated in different research studies (preclinical and clinical) and have also been approved in various jurisdictions. Further, they are likely to be safer for patients and more commercially feasible in the rare disease domain, in the coming future.

To know more about this report visit here